Protalix BioTherapeutics (PLX) Current Deferred Revenue (2010 - 2025)

Protalix BioTherapeutics' Current Deferred Revenue history runs 16 years deep, the most recent figure standing at $2.0 million for Q1 2025.

• On a quarterly basis, Current Deferred Revenue fell 81.88% year-over-year to $2.0 million in Q1 2025; TTM through Mar 2025 was $2.0 million, a 81.88% decrease from a year earlier, with the FY2022 full-year figure at $13.2 million, up 54.13% from the prior year.
• Current Deferred Revenue fell to $2.0 million in Q1 2025 per PLX's latest filing, from $12.7 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $18.1 million in Q2 2021 and bottomed at $2.0 million in Q1 2025.
• The 5-year median for Current Deferred Revenue is $11.8 million (2022), against an average of $11.0 million.
• Across the five-year window, Current Deferred Revenue tumbled 86.54% in 2021 and soared 360.98% in 2022, its largest moves.
• Year by year, Current Deferred Revenue stood at $8.5 million in 2021, then soared by 54.13% to $13.2 million in 2022, then fell by 10.53% to $11.8 million in 2023, then grew by 7.68% to $12.7 million in 2024, then sank by 84.25% to $2.0 million in 2025.
• Per Business Quant, the three latest PLX Current Deferred Revenue figures stand at $2.0 million (Q1 2025), $12.7 million (Q2 2024), and $11.0 million (Q1 2024).